|Bid||49.00 x 1100|
|Ask||0.00 x 1000|
|Day's Range||51.00 - 52.26|
|52 Week Range||32.84 - 89.18|
|Beta (5Y Monthly)||1.15|
|PE Ratio (TTM)||51.80|
|Earnings Date||Apr 25, 2022 - Apr 29, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.40|
AtriCure (ATRC) delivered earnings and revenue surprises of -6.67% and 6.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MASON, Ohio, August 02, 2022--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...